Reuben A. Mesa, MD, from Mayo Clinic Cancer Center, Scottsdale, AZ, describes exciting findings from the RESPONSE trial for polycythemia vera (PV). The phase III RESPONSE trial compared ruxolitinib and best available therapy in patients with PV who were intolerant of or resistant to first-line therapy is hydroxyurea. Researcher found that ruxolitinib was superior to best available therapy in terms of hematocrit, splenomegaly, and achieving a complete remission.

свернуть